Multicenter, phase ii study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1101-1107

  Sasaki, Takashi ^a   Isayama, Hiroyuki ^a   Nakai, Yousuke ^a   Ito, Yukiko ^b   Kogure, Hirofumi ^c   Togawa, Osamu ^d   Toda, Nobuo ^e   Yasuda, Ichiro ^f   Hasebe, Osamu ^g   Maetani, Iruru ^h   Sasahira, Naoki ^a   Hirano, Kenji ^a   Tsujino, Takeshi ^a   Tada, Minoru ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c The Mutualaid Association of Public School Teachers)   (Japan)

^d JR Tokyo General Hospital   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f GIFU UNIVERSITY HOSPITAL   (Japan)

^g Nagano Municipal Hospital   (Japan)

^h TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; Gemcitabine; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; BILIARY TRACT TUMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OXONIC ACID; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 77951928508     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1115-5     Document Type: Article

References (36)

1. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13:415-423
2. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896-902
3. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37:843-851
4. Valle JW, Wasan HS, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton M, Bridgewater JA (2009) Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer (ABC) : results of a multicenter, randomized phase III trial (the UK ABC-02 trial). Proc Am Soc Clin Oncol 27:15s (abstract no: 4503)
5. Furuse J, Okusaka T, Miyazaki M, Tainai H, Nimura Y (2009) A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. Proc Am Soc Clin Oncol 27:15s (abstract no: 4579)
6. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339-1343
7. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O, Henss H (2006) Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 95:848-852
8. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W (2008) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99:862-867
9. Kim HJ, Lee NS, Lee SC, Bae SB, Kim CK, Cheon YG, Kim YS, Moon JH, Cho YD, Park SH, Lee KT, Park SK, Won JH, Park HS, Hong DS (2009) A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 64:371-377
10. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332-2338
11. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104:2753-2758
12. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307-1312
13. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769-1774
14. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849-855
15. Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T, Togawa O, Matsubara S, Ito Y, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77:71-74
16. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575-1579
17. Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH (2009) Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 64:707-713
18. Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS (2009) S-1 and gemcitabine as an outpatientbased regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 39:49-53
19. Kaira K, Sunaga N, Yanagitani N, Aoki H, Kawata T, Utsugi M, Shimizu Y, Shimizu K, Hisada T, Ishizuka T, Mori M (2008) Phase I trial of oral S-1 plus gemcitabine in elderly patients with non-small cell lung cancer. Anticancer Drugs 19:289-294
20. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M (2009) A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology [Epub ahead of print]
21. Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH (2009) A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol [Epub ahead of print]
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
24. van der Weide J, Steijns LS (1999) Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 36(Pt 6):722-729
25. *9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74:69-76
26. *11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12:299-306
27. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957-6965
28. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, Awasthy BS (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gallbladder cancer. Br J Cancer 90:1516-1520
29. Thongprasert S, Napapan S, Charoentum C, Moonprakan S (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279-281
30. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K (2006) A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339-1346
31. Lee J, Kim TY, Lee MA, Ahn MJ, Kim HK, Lim HY, Lee NS, Park BJ, Kim JS (2008) Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 61:47-52
32. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14:1115-1120
33. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK (2007) Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 60:321-328
34. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhofer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B (2008) Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98:309-315
35. Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ (2008) A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 19:99-103
36. Oh SY, Lee GW, Kim HG, Kim TH, Kim HJ, Kang JH (2008) Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer. Chemotherapy 54:479-484